The Role of CircRNAs and MiRNAs in Drug Resistance and Targeted Therapy Responses in Breast Cancer

Overview

Journal Cancer Drug Resist

Date 2024 Sep 13

PMID 39267922

Authors

Meilan Zhang

Zhaokuan Zheng

Shouliang Wang

Ruihan Liu

Mengli Zhang

Zhiyun Guo

Hao Wang

Weige Tan

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs comprising 19-24 nucleotides that indirectly control gene expression. In contrast to other non-coding RNAs (ncRNAs), circular RNAs (circRNAs) are defined by their covalently closed loops, forming covalent bonds between the 3' and 5' ends. circRNAs regulate gene expression by interacting with miRNAs at transcriptional or post-transcriptional levels. Accordingly, circRNAs and miRNAs control many biological events related to cancer, including cell proliferation, metabolism, cell cycle, and apoptosis. Both circRNAs and miRNAs are involved in the pathogenesis of diseases, such as breast cancer. This review focuses on the latest discoveries on dysregulated circRNAs and miRNAs related to breast cancer, highlighting their potential as biomarkers for clinical diagnosis, prognosis, and chemotherapy response.

Citing Articles

Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications.

Benacka R, Szaboova D, Gulasova Z, Hertelyova Z Int J Mol Sci. 2025; 26(1.

PMID: 39795985 PMC: 11719911. DOI: 10.3390/ijms26010127.

References

Tao L, Wu Y, Zhang S . MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4. Neoplasma. 2019; 66(5):746-755. DOI: 10.4149/neo_2018_181207N930. View

Bao S, Hu T, Liu J, Su J, Sun J, Ming Y . Genomic instability-derived plasma extracellular vesicle-microRNA signature as a minimally invasive predictor of risk and unfavorable prognosis in breast cancer. J Nanobiotechnology. 2021; 19(1):22. PMC: 7802300. DOI: 10.1186/s12951-020-00767-3. View

Zhang Z, Zhou Q, Luo F, Zhou R, Xu J, Xiao J . Circular RNA circ-CHI3L1.2 modulates cisplatin resistance of osteosarcoma cells via the miR-340-5p/LPAATβ axis. Hum Cell. 2021; 34(5):1558-1568. DOI: 10.1007/s13577-021-00564-6. View

Ward A, Shukla K, Balwierz A, Soons Z, Konig R, Sahin O . MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol. 2014; 233(4):368-79. PMC: 4298809. DOI: 10.1002/path.4363. View

Nolan E, Lindeman G, Visvader J . Deciphering breast cancer: from biology to the clinic. Cell. 2023; 186(8):1708-1728. DOI: 10.1016/j.cell.2023.01.040. View

Yarmishyn A, Ishola A, Chen C, Verusingam N, Rengganaten V, Mustapha H . Circular RNAs Modulate Cancer Hallmark and Molecular Pathways to Support Cancer Progression and Metastasis. Cancers (Basel). 2022; 14(4). PMC: 8869994. DOI: 10.3390/cancers14040862. View

Zavesky L, Jandakova E, Weinberger V, Minar L, Hanzikova V, Duskova D . Small non-coding RNA profiling in breast cancer: plasma U6 snRNA, miR-451a and miR-548b-5p as novel diagnostic and prognostic biomarkers. Mol Biol Rep. 2022; 49(3):1955-1971. DOI: 10.1007/s11033-021-07010-8. View

Li M, Zou X, Xia T, Wang T, Liu P, Zhou X . A five-miRNA panel in plasma was identified for breast cancer diagnosis. Cancer Med. 2019; 8(16):7006-7017. PMC: 6853814. DOI: 10.1002/cam4.2572. View

Tafrihi M, Hasheminasab E . MiRNAs: Biology, Biogenesis, their Web-based Tools, and Databases. Microrna. 2018; 8(1):4-27. DOI: 10.2174/2211536607666180827111633. View

10.

Satomi-Tsushita N, Shimomura A, Matsuzaki J, Yamamoto Y, Kawauchi J, Takizawa S . Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer. PLoS One. 2019; 14(9):e0222024. PMC: 6726239. DOI: 10.1371/journal.pone.0222024. View

11.

Ashwal-Fluss R, Meyer M, Pamudurti N, Ivanov A, Bartok O, Hanan M . circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014; 56(1):55-66. DOI: 10.1016/j.molcel.2014.08.019. View

12.

Wang Z, Yang L, Wu P, Li X, Tang Y, Ou X . The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin. Mol Cancer. 2022; 21(1):29. PMC: 8785480. DOI: 10.1186/s12943-022-01498-9. View

13.

Chen L . The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016; 17(4):205-11. DOI: 10.1038/nrm.2015.32. View

14.

Jhaveri K, Marme F . Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Cancer Treat Rev. 2024; 123:102670. DOI: 10.1016/j.ctrv.2023.102670. View

15.

Boscolo Bielo L, Trapani D, Nicolo E, Valenza C, Guidi L, Belli C . The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer. Cancer Treat Rev. 2024; 128:102761. DOI: 10.1016/j.ctrv.2024.102761. View

16.

Purrahman D, Mahmoudian-Sani M, Saki N, Wojdasiewicz P, Kurkowska-Jastrzebska I, Poniatowski L . Involvement of progranulin (PGRN) in the pathogenesis and prognosis of breast cancer. Cytokine. 2022; 151:155803. DOI: 10.1016/j.cyto.2022.155803. View

17.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

18.

Zhong W, Bao L, Yuan Y, Meng Y . CircRASSF2 acts as a prognostic factor and promotes breast cancer progression by modulating miR-1205/HOXA1 axis. Bioengineered. 2021; 12(1):3014-3028. PMC: 8806576. DOI: 10.1080/21655979.2021.1933300. View

19.

Yang W, Gong P, Yang Y, Yang C, Yang B, Ren L . Circ-ABCB10 Contributes to Paclitaxel Resistance in Breast Cancer Through Let-7a-5p/DUSP7 Axis. Cancer Manag Res. 2020; 12:2327-2337. PMC: 7108723. DOI: 10.2147/CMAR.S238513. View

20.

Cataldo A, Cheung D, Balsari A, Tagliabue E, Coppola V, Iorio M . miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget. 2015; 7(1):786-97. PMC: 4808033. DOI: 10.18632/oncotarget.6381. View